A potential therapy for diabetes being developed by the biotech company Xoma in partnership with the French pharma firm Servier failed to meet the primary endpoint in a phase IIb study.
The therapy, a monoclonal antibody known as Xoma 052, did not sufficiently reduce glycosylated haemoglobin, or HbA1c, in type II diabetes patients in the placebo-controlled study.
via pmlive.com
No comments:
Post a Comment